Oseltamivir (Rx)
Dosing & Uses
Dosage forms and powers
Capsule
• 30mg
• 45mg
• 75mg
• 30mg
• 45mg
• 75mg
Powder for oral suspension
• 6mg / ml
• 6mg / ml
Influenza A and B Prophylaxis
• 75 mg PO qday for at least 10 days
Dosage ideas
• Start within 48 hours of Exposure
• For community outbreaks, you can administer for 6 weeks
• Start within 48 hours of Exposure
• For community outbreaks, you can administer for 6 weeks
Influenza A and B Treatment
• 75 mg PO q12hr x5 day
Dosage Ideas
• Begin the influenza symptom within 48 hours of starting
• Begin the influenza symptom within 48 hours of starting
H1N1 Influenza A (Swine Flu) Prophylaxis (Off-label)
75 mg PO qDay
Dosage Ideas
• Postexposure prophylaxis: Begin within 7 days of exposure and continue for at least 10 days
• Preexposure prophylaxis: Start during the potential exposure period and continue after 10 days of the last known exposure.
• Postexposure prophylaxis: Begin within 7 days of exposure and continue for at least 10 days
• Preexposure prophylaxis: Start during the potential exposure period and continue after 10 days of the last known exposure.
H1N1 Influenza A (Swine Flu) Treatment (off-label)
75 mg PO q12hr x5 day
Dosage Ideas
• Begin the influenza symptom within 48 hours of starting
• Begin the influenza symptom within 48 hours of starting
Dose modification
Renal impairment
Treatment
• CRCL> 60 mL / min: no dose adjustment is necessary
• CRCL> 30 to 60 mL / min: 30 mg PO bid
• CRCL> 10 to 30 mL / min: 30 mg po qday
• End-stage kidney disease (do not undergo dialysis): Not recommended (not studied)
Prophylaxis
• CRCL> 60 mL / min: no dose adjustment is necessary
• CRCL> 30 to 60 mL / min: 30 mg po qday
• CRCL> 10 to 30 mL / min: 30 mg PO every other day
• End-stage kidney disease (do not undergo dialysis): Not recommended (not studied)
• CRCL> 60 mL / min: no dose adjustment is necessary
• CRCL> 30 to 60 mL / min: 30 mg PO bid
• CRCL> 10 to 30 mL / min: 30 mg po qday
• End-stage kidney disease (do not undergo dialysis): Not recommended (not studied)
Prophylaxis
• CRCL> 60 mL / min: no dose adjustment is necessary
• CRCL> 30 to 60 mL / min: 30 mg po qday
• CRCL> 10 to 30 mL / min: 30 mg PO every other day
• End-stage kidney disease (do not undergo dialysis): Not recommended (not studied)
Interections
Clopidogrel
Clopidogrel reduces oseltamivir levels by others (see note). Use caution / monitor. Remarks: Clopidogrel can reduce serum concentrations of active metabolite (S) of oseltamivir. .
Influenza virus vaccine quadrivalent
The influenza virus vaccine by oseltamivir pharmacodynamic rivalry reduces the effect of quadrivalent. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of oseltamivir, unless prescribed for medical signs.
Influenza virus vaccine quadrivalent, intranasal
The influenza virus vaccine by oseltamivir pharmacodynamic rivalry reduces the effect of quadrivalent, intranasal. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of Oseltamivir, unless prescribed for medical signs.
Influenza virus vaccine quadrivalent, recombinant
Oseltamivir pharmacodynamic rivalry reduces the effect of recombinant, influenza virus vaccine quadrivalent. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of Oseltamivir, unless prescribed for medical signs.
Influenza virus vaccine trivalent
Oseltamivir reduces the effect of triangular influenza virus vaccine by pharmacodynamic antioxidants. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of Oseltamivir, unless prescribed for medical signs.
Influenza virus vaccine trivalent, adjuvanted
Oseltamivir pharmacodynamic anti-influenza virus vaccine reduces the effect of trivalent by anti-virus. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of Oseltamivir, unless prescribed for medical signs.
Influenza virus vaccine trivalent, recombinant
Oseltamivir reduces the effect of the recombinant influenza virus vaccine trivalent by pharmacodynamic rivalry. Use caution / monitor. Avoid the administration of live-influenza influenza vaccine intravenous, within 2 weeks or 48 hours after the administration of Oseltamivir, unless prescribed for medical signs.
Probenecid
The level of oseltamivir increases by probenecid other. Use caution / monitor. Note: Classification results of probenecid results in 2x increase in contact with oseltamivir carboxylate due to a decrease in active anionic tubular secretion in the kidney. No dosage adjustments are required with probenecid coadministration.
Adverse Effect
1-10%
• Stomach Pain
• Conjunctivitis
• Ear disorder
• Bleeding nose
• Insomnia
• Nausea
• Vomiting
• Vertigo Read More
• Stomach Pain
• Conjunctivitis
• Ear disorder
• Bleeding nose
• Insomnia
• Nausea
• Vomiting
• Vertigo Read More
from Dr. Linex http://bit.ly/2CGiKxK
via IFTTT
0 comments:
Post a Comment